Lung Cancer

Disease Group

Lung Cancer

Disease Group Profile

The thoracic malignancy disease group was established in 2021 to direct the lung cancer and mesothelioma research activities of ACCRU. It is led by Dr. Stephen Liu, the Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, Dr. Aaron Mansfield, Professor of Oncology at Mayo Clinic Cancer Center, and Dr. Bryan Faller, Medical Director of Cancer Research at Missouri Baptist Medical Center in St. Louis, MO.

Disease Group Leaders

Bryan Faller
Bryan Faller, M.D.

Heartland NCI Community Oncology Research Program

Bryan Faller, M.D. a community medical oncologist based in St. Louis, Missouri, is the Alan P. Lyss Endowed Chair in Cancer Research at Missouri Baptist Medical Center and the PI of Heartland Cancer Research NCI Community Oncology Research Program (NCORP). He has served on the ACCRU Scientific and Administrative Review Committee since 2013 and on the ACCRU Board of Directors since 2018.

Stephen Liu, M.D.

MedStar Georgetown University Hospital

Stephen Liu, M.D. is the Director of Thoracic Oncology and Head of Developmental Therapeutics at Georgetown University Lombardi Comprehensive Cancer Center. He is a medical oncologist focused on the treatment of lung cancer with extensive experience in immunotherapy, targeted therapy, and rational clinical trial design.

Aaron Mansfield, M.D.

Mayo Clinic Rochester

Aaron Mansfield, M.D. is a medical oncologist with expertise in the treatment of thoracic malignancies. His efforts have supported FDA-approval of multiple novel therapeutics for lung cancers, mesothelioma, and thyroid malignancies. His NIH, DoD and Mark Foundation funding have supported the development of novel biomarkers.

Disease Group Clinical Trials

No posts found.
No posts found.
A7471042

Archer 1042: A Phase 2 Study Of Dacomitinib In Advanced Non-small Cell Lung Cancer (Post-chemotherapy Or Select First Line Patients) To Evaluate Prophylactic Intervention On Dermatologic And Gastrointestinal Adverse Events And Patient Reported Outcomes

Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO (ARCHER 1042) »

RC0524

A Randomized Phase II Study of ALIMTA? (Pemetrexed) and GEMZAR? (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer

Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer »

RC0527

A Randomized Phase II Study of ALIMTA? (Pemetrexed) and GEMZAR? (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer

Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524 »

RC1126

A Randomized Phase II Trial of Erlotinib Alone or In Combination with Bevacizumab in Patients with Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations »